Iryna's Law (A 2946) creates a process for prosecutors to request mental health screenings for eligible defendants with mental illness who pose a danger to self or others, potentially avoiding pretrial jail detention. It allows prosecutors to file motions after arrest to immediately transport such defendants to a screening service, which determines if they need involuntary mental health treatment instead of pretrial detention. The law applies to defendants not previously involuntarily committed within the past three years and establishes an aggravating factor for offenses committed in certain public places. This directly affects defendants facing charges who may qualify for mental health evaluation rather than standard pretrial detention. The bill amends New Jersey's pretrial release and sentencing statutes to prioritize mental health assessment for specific cases.
This bill requires New Jersey colleges to keep naloxone nasal spray in secure, accessible locations across campus residence halls for opioid overdose emergencies. It permits licensed medical staff (like nurses or doctors) and trained resident assistants to administer the medication during suspected overdoses, based on their good-faith belief. Institutions must develop policies designating a medical supervisor, requiring staff training on proper administration and overdose prevention, and mandating hospital transport after naloxone use - even if symptoms improve. The law also provides liability protection for good-faith actions by medical staff, resident assistants, or pharmacists following the bill's guidelines.
This non-binding resolution urges New Jersey's Attorney General to establish mandatory in-service training for all state law enforcement officers. It specifically recommends requiring a minimum of two hours of training every three years focused on interacting with developmentally disabled individuals and those experiencing behavioral health crises. The resolution notes that while basic officer training includes some awareness of these topics, statewide mandatory in-service requirements are currently lacking. It suggests using free NJLearn programs as a potential training resource and recommends guidelines for implementation. As a resolution, it does not create new law but seeks to influence training standards for law enforcement.
This bill permanently requires New Jersey health insurance carriers to pay the same reimbursement rate for telemedicine and telehealth services as they do for in-person visits, provided the service is otherwise covered. It ensures patients face no higher deductibles, copays, or coinsurance for telehealth compared to in-person care. The law prohibits insurers from restricting where telehealth services can occur, limiting which technology platforms providers can use, or denying coverage for routine remote monitoring. It directly affects health insurance companies, healthcare providers offering telehealth, and patients receiving covered telehealth services. The policy change applies to all health benefits plans in New Jersey without time limits.
This bill establishes a $1 million grant program to expand mental health services for military-connected students in New Jersey school districts. It targets districts with high concentrations of students who have parents or guardians serving in the military (active duty, National Guard, or reserves), requiring applicants to demonstrate this concentration and outline their specific mental health needs. Grant funds can be used for counseling, outreach, and improving existing mental health services for these students, particularly during parental deployments. School districts receiving grants must report annually on service usage and outcomes, and the Department of Education must submit a program evaluation to the Governor and Legislature within two years.
This bill requires New Jersey's State Long-Term Care Ombudsman to assign paid or volunteer advocates to work directly at long-term care facilities. These advocates must conduct in-person visits with residents to help address their financial, health, legal, and social needs. The bill mandates an appropriation from the General Fund to cover the costs of these assigned advocates. It directly affects residents of long-term care facilities by ensuring they have on-site support to advocate for their needs. The policy change is a concrete requirement for the ombudsman's office to implement, funded by the state.
This bill requires New Jersey hospitals to report prescription drug pricing data to the Division of Consumer Affairs. It mandates hospitals (defined as general acute care hospitals licensed under state law) to submit accurate data on drug costs, including wholesale acquisition cost, under penalty of perjury. Non-compliance could result in civil penalties starting at $10,000 for the first day of violation and increasing up to $100,000 per day. The law also authorizes audits and corrective action plans for reporting deficiencies. This directly affects hospitals and other entities required to report drug pricing data under the amended statute.
This bill (A4336) requires licensed healthcare providers to give a menopause information pamphlet to female patients aged 35-39 during their annual physical exams, starting 180 days after the law takes effect. The pamphlet, created by the New Jersey Department of Health within 90 days of the law's effective date, covers premature menopause, early menopause, and primary ovarian insufficiency. It aims to provide standardized educational resources during routine healthcare visits for this age group. The bill directly affects healthcare providers conducting these exams and female patients in the specified age range.
This bill establishes a $6 million pilot program to study psilocybin therapy for behavioral health conditions like depression and anxiety through New Jersey hospitals. It directs the Department of Health to select participating hospitals across three regions (Central, Northern, Southern) to conduct FDA- and DEA-compliant research, with oversight from a new advisory board. The program aims to evaluate whether a future statewide system for safe, legal psilocybin therapy could be developed, focusing on treatment-resistant depression and other conditions. The bill was withdrawn after being approved as part of P.L.2025, c.296, meaning it is now law but no longer pending.
This bill requires all over-the-counter and prescription drugs containing ingredients derived from common food allergens (like peanuts or shellfish) or gluten-containing grains (like wheat) to display clear, visible labels identifying those specific ingredients. It directly affects drug manufacturers and pharmacies by mandating this labeling on product packaging. The Department of Health will enforce the rule, with penalties of $500 for a first offense, $1,000 for a second, and $2,000 for subsequent violations. The goal is to help consumers with allergies or sensitivities safely identify and avoid potentially harmful ingredients in medications.
